Other languages Prime Medicine, Inc.

Equities

PRME

US74168J1016

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
6.66 ^USD	+3.74%		+19.57%	-24.83%

May. 13	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating	MT
May. 10	Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10
Prime Medicine Shares Jump After Application for Chronic Granulomatous Disease Treatment Gets FDA Clearance	Apr. 29
Prime Medicine Announces FDA Clearance of Investigational New Drug Application for PM359 for the Treatment of Chronic Granulomatous Disease	Apr. 29
Prime Medicine 2023 Net Loss Narrows	Mar. 01
Prime Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 01
Prime Medicine Prices $140 Million Upsized Offering	Feb. 15
Prime Medicine to Get $15 Million Grant for Cystic Fibrosis Treatment	Jan. 25
Prime Medicine Names Foghorn Therapeutics' CFO to be its New Finance Chief	Jan. 05
Prime Medicine, Inc. Announces Executive Changes, Effective January 17, 2024	Jan. 05
Prime Medicine Files $500 Million Mixed Shelf	Nov. 06
Prime Medicine, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 03
Prime Medicine's Q3 Loss Narrows	Nov. 03
Prime Medicine, Inc. Presents First-Ever Prime Editing Data in Non-Human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-Causing Mutation of Gsd1b	23-10-27
Prime Medicine, Inc. Presents First in Vivo Proof-Of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases	23-10-24
Prime Medicine, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07
MaxCyte Grants Rights to Prime Medicine to Use ExPERT Platform	23-08-01
MaxCyte strikes deal; Barkby sells Workshop	23-08-01
Prime Medicine, Cimeio Therapeutics Unveil Research Partnership to Improve Treatment of Genetic Diseases	23-06-22
Prime Medicine and Cimeio Therapeutics Announce Research Collaboration to Develop Prime Edited Shielded-Cell & Immunotherapy Pairs(Tm) for Genetic Diseases, Acute Myeloid Leukemia and Myelodysplastic Syndrome	23-06-22
Insider Sell: Prime Medicine	23-06-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Prime Medicine, Inc.

Equities

PRME

US74168J1016

Other languages

Filters